Kisho

Kisho is an information platform, not a medical provider. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. All content is aggregated from publicly available sources (including ClinicalTrials.gov, PubMed, FDA.gov, and Orphanet) and is provided for informational purposes only. Clinical trial eligibility, treatment decisions, and any health-related actions should always be discussed with a qualified healthcare professional. Kisho does not endorse any specific therapy, organization, or clinical trial. Terms of use · Privacy policy

B-cell acute lymphoblastic leukemia - Clinical Profile, Treatments & Trials | Kisho | Kisho

Rare Disease

B-cell acute lymphoblastic leukemia

MONDO:0004947

Also known as:B lymphoblastic leukemia/lymphomaprecursor B lymphoblastic leukemia/lymphomaprecursor B-lymphoblastic lymphoma/leukemia

Find Clinical TrialsTrials

Overview

A neoplasm of lymphoblasts committed to the B-cell lineage, typically composed of small to medium-sized blast cells. When the neoplasm involves predominantly the bone marrow and the peripheral blood, it is called B acute lymphoblastic leukemia. When it involves nodal or extranodal sites, it is called B lymphoblastic lymphoma. (WHO, 2001)

Treatments2 FDA approved, incl. 1 gene therapy

Clinical Trials135 registered · 54 recruiting

Diagnosis

Biomarker and diagnostic research for B-cell acute lymphoblastic leukemia has been reported in the published literature.

Treatment

Compiled from FDA-approved drug records, orphan drug designations, and FDA Adverse Event Reporting System (FAERS) safety data. GeneReviews management guidance is included where available.

2 FDA-approved treatments are available for B-cell acute lymphoblastic leukemia, including brexucabtagene autoleucel (Tecartus, approved 2020) and INOTUZUMAB OZOGAMICIN (BESPONSA, approved 2017).

Approved Therapies

Brand Name	Generic Name	Mechanism	Approved	Market Status

Research Landscape

Sourced from ClinicalTrials.gov and PubMed. Publication types are classified using NLM-curated article metadata; research type breakdowns reflect the nature of published work for this disease.

135 clinical trials registered, 54 recruiting. Interventions under study include drug therapy, biologic therapy, other interventions, and procedural interventions. Pipeline includes 8 PHASE3, 38 PHASE2, 57 PHASE1. Research is sponsored by a mix of industry and academic institutions.

NCT ID	Title	Phase	Sponsor	Status
[NCT03959085](https://clinicaltrials.gov/study/NCT03959085)

Data assembled from 4 of 12 sources · Last updated Sep 19, 2026, 6:00 AM UTC

MONDOHPOClinicalTrials.govFDAPubMedHGNCClinVarClinGenGeneReviewsOrphanetOMIMRUSP

Patient Support

Financial & Access Support (External Programs)

View all programs →

Acute Lymphoblastic Leukemia Program

Premium/CopayClosedOperated by Good Days

Visit official site

Program availability and eligibility requirements are set by each foundation. Contact them directly to learn more about your options.

Are you a patient organization for this condition?

Claim this page and your organization will be listed here for patients and families to find.

Be recognized as the official organization
Get notified of new trials, FDA decisions, and research
Appear in the disease page directory
Embed this content on your website — free

Medical References

Questions for Your Care Team

→What are the eligibility criteria and monitoring requirements for Tecartus?
→What are the benefits and potential side effects of BESPONSA for managing B-cell acute lymphoblastic leukemia?
→Are any of the 135 active clinical trials a good fit for my situation?
→Are there specialists or centers of excellence for this condition in my area?
→Is there a patient registry I should consider joining?

← Back to All Diseases

Research Type	Count	% of Total
Research summaries	72	26%
Laboratory research	65	23%
Clinical study results	57	20%
Patient case studies	27	10%
Testing and diagnosis research	19	7%
Disease patterns and progression	19	7%
New treatment approaches	15	5%
Other research	6	2%

Kisho

B-cell acute lymphoblastic leukemia

Overview

Diagnosis

Treatment

Approved Therapies

Research Landscape

Patient Support

Financial & Access Support (External Programs)

Are you a patient organization for this condition?

Medical References

Questions for Your Care Team

Questions for Your Care Team

Clinical Trials

Recent Publications

Latest News & Developments

An unusual cranial manifestation of B-cell precursor lymphoblastic lymphoma in 10-year-old girl.

Spontaneous regression of B-cell acute lymphoblastic leukemia with PAX5 alterations at relapse: a case report.

An Unusual Presentation of Philadelphia Chromosome Positive B-Cell Acute Lymphoblastic Leukemia With Isolated Osteolytic Lesions at Diagnosis: A Case Report.

Inotuzumab Ozogamicin Outcomes in ALL Validated Outside of Clinical Trials | AJMC

B-cell acute lymphoblastic leukemia

Overview

Diagnosis

Treatment

Approved Therapies

Research Landscape

Patient Support

Financial & Access Support (External Programs)

Are you a patient organization for this condition?

Medical References

Related Diseases

Questions for Your Care Team

Questions for Your Care Team

Clinical Trials

Recent Publications

Latest News & Developments

An unusual cranial manifestation of B-cell precursor lymphoblastic lymphoma in 10-year-old girl.

Spontaneous regression of B-cell acute lymphoblastic leukemia with PAX5 alterations at relapse: a case report.

An Unusual Presentation of Philadelphia Chromosome Positive B-Cell Acute Lymphoblastic Leukemia With Isolated Osteolytic Lesions at Diagnosis: A Case Report.

Inotuzumab Ozogamicin Outcomes in ALL Validated Outside of Clinical Trials | AJMC